S. Keith Anderson

5.7k total citations · 2 hit papers
59 papers, 3.4k citations indexed

About

S. Keith Anderson is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, S. Keith Anderson has authored 59 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 27 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in S. Keith Anderson's work include Glioma Diagnosis and Treatment (32 papers), Brain Metastases and Treatment (16 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). S. Keith Anderson is often cited by papers focused on Glioma Diagnosis and Treatment (32 papers), Brain Metastases and Treatment (16 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). S. Keith Anderson collaborates with scholars based in United States, Canada and Switzerland. S. Keith Anderson's co-authors include Karla V. Ballman, Evanthia Galanis, Jan C. Buckner, Paul D. Brown, Jane H. Cerhan, Xiomara W. Carrero, Elana Farace, Fred G. Barker, Kurt A. Jaeckle and Caterina Giannini and has published in prestigious journals such as JAMA, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

S. Keith Anderson

56 papers receiving 3.3k citations

Hit Papers

Effect of Radiosurgery Alone vs Radiosurgery With Whole B... 2016 2026 2019 2022 2016 2017 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
    2016 1.1k citations Paul D. Brown, Kurt A. Jaeckle et al. profile →
  2. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
    2017 772 citations Paul D. Brown, Karla V. Ballman et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Keith Anderson United States 23 2.3k 1.8k 1.4k 617 512 59 3.4k
Wenyin Shi United States 30 1.7k 0.7× 1.3k 0.7× 832 0.6× 561 0.9× 661 1.3× 181 3.4k
Nina A. Paleologos United States 25 2.3k 1.0× 3.4k 1.9× 1.5k 1.1× 745 1.2× 852 1.7× 49 5.0k
Ashwatha Narayana United States 29 1.3k 0.6× 1.2k 0.7× 808 0.6× 406 0.7× 485 0.9× 64 3.0k
Baldassarre Stea United States 28 1.4k 0.6× 877 0.5× 1.0k 0.7× 293 0.5× 503 1.0× 117 3.1k
Ronald E. Warnick United States 32 1.2k 0.5× 1.7k 1.0× 696 0.5× 1.1k 1.9× 936 1.8× 101 3.8k
Dieta Brandsma Netherlands 27 1.9k 0.8× 2.4k 1.4× 1.3k 0.9× 999 1.6× 505 1.0× 93 4.4k
Lawrence Kleinberg United States 41 2.8k 1.2× 2.3k 1.3× 1.5k 1.1× 938 1.5× 543 1.1× 230 5.5k
Alessia Pica Switzerland 22 869 0.4× 1.2k 0.7× 369 0.3× 615 1.0× 407 0.8× 100 2.6k
Alicia Tosoni Italy 29 1.3k 0.6× 2.9k 1.6× 771 0.6× 722 1.2× 1.1k 2.2× 103 4.2k
Gregory Cairncross Canada 19 1.4k 0.6× 3.0k 1.7× 428 0.3× 783 1.3× 764 1.5× 41 3.7k

Countries citing papers authored by S. Keith Anderson

Since Specialization
Citations

This map shows the geographic impact of S. Keith Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Keith Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Keith Anderson more than expected).

Fields of papers citing papers by S. Keith Anderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Keith Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Keith Anderson. The network helps show where S. Keith Anderson may publish in the future.

Co-authorship network of co-authors of S. Keith Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of S. Keith Anderson. A scholar is included among the top collaborators of S. Keith Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Keith Anderson. S. Keith Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Allain, Thibault, et al.. (2024). Giardia spp.-induced microbiota dysbiosis disrupts intestinal mucin glycosylation. Gut Microbes. 16(1). 2412676–2412676. 3 indexed citations
3.
Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations
4.
Parney, Ian F., S. Keith Anderson, Michael P. Gustafson, et al.. (2022). Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. Neuro-Oncology Advances. 4(1). vdac089–vdac089. 14 indexed citations
5.
Laack, Nadia N., Deanna Pafundi, S. Keith Anderson, et al.. (2021). Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 110(5). 1383–1395. 40 indexed citations
6.
7.
Cerhan, Jane H., Chip Caine, S. Keith Anderson, et al.. (2018). Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. Neuro-Oncology Practice. 6(1). 71–77. 7 indexed citations
8.
Brown, Paul D., Karla V. Ballman, Jane H. Cerhan, et al.. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology. 18(8). 1049–1060. 772 indexed citations breakdown →
9.
10.
Perez, Edith A., E. Aubrey Thompson, Karla V. Ballman, et al.. (2015). Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 33(7). 701–708. 144 indexed citations
11.
Brown, Paul E., Anthony L. Asher, Karla V. Ballman, et al.. (2015). BMET-05NCCTG N0574 (ALLIANCE): A PHASE III RANDOMIZED TRIAL OF WHOLE BRAIN RADIATION THERAPY (WBRT) IN ADDITION TO RADIOSURGERY (SRS) IN PATIENTS WITH 1 TO 3 BRAIN METASTASES. Neuro-Oncology. 17(suppl 5). v45.5–v46. 18 indexed citations
12.
Perez, Edith A., Karla V. Ballman, S. Keith Anderson, et al.. (2015). Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. Cancer Research. 75(9_Supplement). S1–6. 17 indexed citations
13.
Daniel, J., Evanthia Galanis, S. Keith Anderson, et al.. (2014). A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology. 17(9). 1261–1269. 122 indexed citations
14.
Perez, Edith A., E. Aubrey Thompson, S. Keith Anderson, et al.. (2014). Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.. Journal of Clinical Oncology. 32(15_suppl). 509–509. 9 indexed citations
15.
Mahoney, Douglas W., Terry M. Therneau, S. Keith Anderson, et al.. (2013). Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Research Notes. 6(1). 33–33. 9 indexed citations
16.
Galanis, Evanthia, S. Keith Anderson, Joon H. Uhm, et al.. (2013). Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research. 19(17). 4816–4823. 127 indexed citations
17.
Heemers, Hannelore V., Lucy J. Schmidt, Zhifu Sun, et al.. (2011). Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer. Cancer Research. 71(5). 1978–1988. 35 indexed citations
18.
Reinholz, Monica M., Jeanette E. Eckel‐Passow, S. Keith Anderson, et al.. (2010). Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL®platform. BMC Medical Genomics. 3(1). 60–60. 11 indexed citations
19.
Anderson, S. Keith, et al.. (2009). Aicardi Syndrome in a Male Patient. Neuropediatrics. 40(1). 39–42. 5 indexed citations
20.
Heemers, Hannelore V., Kevin M. Regan, Lucy J. Schmidt, et al.. (2009). Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. Molecular Endocrinology. 23(4). 572–583. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenyin Shi Breakdown of academic impact, for papers by Nina A. Paleologos Breakdown of academic impact, for papers by Ashwatha Narayana Breakdown of academic impact, for papers by Baldassarre Stea Breakdown of academic impact, for papers by Ronald E. Warnick Breakdown of academic impact, for papers by Dieta Brandsma Breakdown of academic impact, for papers by Lawrence Kleinberg Breakdown of academic impact, for papers by Alessia Pica Breakdown of academic impact, for papers by Alicia Tosoni Breakdown of academic impact, for papers by Gregory Cairncross
Rankless by CCL
2026